ICCM · IceCure Medical Ltd. Ordinary Shares
View on chartInsiders & Stakes
| Peleg Meir Chief Financial Officer | ▲ Buy | Grant | 194,816 Shares held | 8/14/2026 | View profile |
| Levav Shay Chief Operating Officer | ▲ Buy | Grant | 146,303 Shares held | 8/14/2026 | View profile |
| Good Shad VP, Sales for North America | ▲ Buy | Grant | 136,698 Shares held | 8/14/2026 | View profile |
| Tel-Tzure Tlalit Bussi VP, BD & Global Marketing | ▲ Buy | Grant | 106,518 Shares held | 8/14/2026 | View profile |
| Dotan Merav Nir VP, Human Resources | ▲ Buy | Grant | 76,168 Shares held | 8/14/2026 | View profile |
Transaction History
| Good Shad | ▲ Buy | Grant | 131,483 | $0 | 8/14/2026 |
| Tel-Tzure Tlalit Bussi | ▲ Buy | Grant | 101,483 | $0 | 8/14/2026 |
| Levav Shay | ▲ Buy | Grant | 141,483 | $0 | 8/14/2026 |
| Dotan Merav Nir | ▲ Buy | Grant | 73,890 | $0 | 8/14/2026 |
| Peleg Meir | ▲ Buy | Grant | 181,483 | $0 | 8/14/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
ICCM Adds Legacy Health Site for Prosense Cryoablation Study
IceCure Medical announced it has added Legacy Health in Portland, Oregon, as a new U.S. clinical site for its post‑marketing ChoICE study of Prosense Cryoablation. The expansion increases the number of patients enrolled in the low‑risk breast cancer trial, which could provide more robust safety and efficacy data. The study is part of the company’s effort to support the market launch of its cryoablation technology. The addition is a routine development in the company’s clinical program.
ICCM Adds Legacy Health Site for Prosense Cryoablation Study. IceCure Medical announced it has added Legacy Health in Portland, Oregon, as a new U.S. clinical site for its post‑marketing ChoICE study of Prosense Cryoablation. The expansion increases the number of patients enrolled in the low‑risk breast cancer trial, which could provide more robust safety and efficacy data. The study is part of the company’s effort to support the market launch of its cryoablation technology. The addition is a routine development in the company’s clinical program.